4.5 Article

NCCN Guidelines® Insights Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0059

关键词

-

类别

资金

  1. Astellas
  2. AstraZeneca
  3. Celldex Therapeutics
  4. Clovis Oncology
  5. Genomic Health, Inc.
  6. Kyowa Hakko Kirin
  7. Jazz Pharmaceuticals
  8. Novartis Pharmaceuticals Corporation
  9. NOVOCURE
  10. Merck Co., Inc.

向作者/读者索取更多资源

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据